IP Library Patent Application 13031175
Patent Application
App. No. 13/031,175

DHA Triglyceride Emulsions

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/031,175
Abstract

The present invention is directed to an emulsion comprising an emulsifier, an isotonic agent and a docosahexaenoic acid triglyceride (DHA-TG) wherein the emulsion is substantially free of eicosapentaenoic acid (EPA) and is suitable for parenteral administration.

Claims (33)

1 . An emulsion comprising an emulsifier, an isotonic agent and about 100 mg/ml to 300 mg/ml docosahexaenoic acid triglyceride (DHA-TG) wherein the emulsion is provided substantially free of eicosapentaenoic acid (EPA) and is suitable for parenteral administration.

2 . The emulsion as recited in claim 1 , further comprising from about 0.03% to about 0.4% of a secondary emulsifier, by weight, of the emulsion.

3 . The emulsion as recited in claim 2 , wherein the secondary emulsion comprises about 0.03% to about 0.3%, by weight, of the emulsion.

4 . The emulsion as recited in claim 2 , wherein the secondary emulsifier is selected from the group consisting of linoleic acid, linolenic acid, oleic acid, and palmitic acid and their pharmaceutically acceptable salts.

5 . The emulsion as recited in claim 3 , wherein the secondary emulsifier is selected from the group consisting of linoleic acid, linolenic acid, oleic acid, and palmitic acid and their pharmaceutically acceptable salts.

6 . The emulsion as recited in claim 2 , wherein the secondary emulsifier is sodium oleate.

7 . The emulsion as recited in claim 2 , wherein the secondary emulsifier is sodium oleate.

8 . The emulsion as recited in claim 7 , comprising the sodium oleate is about 0.3% by weight.

9 . The emulsion as recited in claim 1 , wherein the concentration of the DHA-TG is about 144 mg/ml to about 300 mg/ml of the emulsion.

10 . The emulsion as recited in claim 2 , wherein the concentration of the DHA-TG is about 144 mg/ml to about 300 mg/ml of the emulsion.

11 . The emulsion as recited in claim 3 , wherein the concentration of the DHA-TG is about 144 mg/ml to about 300 mg/ml of the emulsion.

12 . The emulsion as recited in claim 4 , wherein the concentration of the DHA-TG is about 144 mg/ml to about 300 mg/ml of the emulsion.

13 . The emulsion as recited in claim 5 , wherein the concentration of the DHA-TG is about 144 mg/ml to about 300 mg/ml of the emulsion.

14 . The emulsion as recited in claim 6 , wherein the concentration of the DHA-TG is about 144 mg/ml to about 300 mg/ml of the emulsion.

15 . The emulsion as recited in claim 7 , wherein the concentration of the DHA-TG is about 144 mg/ml to about 300 mg/ml of the emulsion.

16 . The emulsion as recited in claim 8 , wherein the concentration of the DHA-TG is about 144 mg/ml to about 300 mg/ml of the emulsion.

17 . The emulsion as recited in claim 9 , wherein the concentration of the DHA-TG is about 114 mg/ml to about 180 mg/ml of the emulsion.

18 . The emulsion as recited in claim 17 , wherein the concentration of the DHA-TG is about 114 mg/ml to about 126 mg/ml of the emulsion.

19 . The emulsion as recited in claim 9 , wherein the concentration of the DHA-TG is about 165 mg/ml to about 171 mg/ml of the emulsion.

20 . The emulsion as recited in claim 9 , wherein the concentration of the DHA-TG is about 120 mg/ml.

21 . The emulsion as recited in claim 9 , wherein the concentration of the DHA-TG is about 180 mg/ml.

22 . The emulsion as recited in claim 1 , wherein the mean particle size of the emulsion is less than about 500 nanometers.

23 . The emulsion as recited in claim 1 , wherein the emulsion comprises about 0.6% to about 10%, by weight, of the emulsifier.

24 . The emulsion as recited in claim 23 , wherein the emulsion comprises about 1% to about 4%, by weight, of the emulsifier.

25 . The emulsion as recited in claim 1 , wherein the emulsion comprises about 1% to about 5%, by weight, of the isotonic agent.

26 . The emulsion as recited in claim 25 , wherein the emulsion comprises about 2.25% to about 2.5%, by weight, of the isotonic agent.

27 . The emulsion as recited in claim 1 , wherein the emulsion is substantially free of arachidonic acid (ARA).

28 . The emulsion as recited in claim 1 , wherein the isotonic agent comprises glycerin.

29 . The emulsion as recited in claim 1 , wherein the emulsifier comprises a lecithin.

30 . An emulsion comprising about 120 milligrams of DHA-TG per milliliter of the emulsion; about 18 milligrams of a lecithin per milliliter of the emulsion; and about 25 milligrams of glycerin per milliliter of the emulsion wherein the emulsion has a mean particle less than about 500 nanometers and wherein the emulsion is substantially free of EPA and is suitable for parenteral administration.

31 . The emulsion as recited in claim 30 , further comprising about 0.3 milligrams of sodium oleate per milliliter of the emulsion.

32 . An emulsion comprising about 165 milligrams to about 180 milligrams of DHA-TG per milliliter of the emulsion; about 18 milligrams lecithin per milliliter of the emulsion; and about 25 milligrams of glycerin per milliliter of the emulsion wherein the emulsion has a mean particle size of about less than 500 nanometers wherein the emulsion is substantially free of EPA and is suitable for parenteral administration.

33 . The emulsion as recited in claim 32 , further comprising about 0.3 milligrams of sodium oleate per milliliter of the emulsion.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2012
From: MARTEK BIOSCIENCES CORPORATION
To: DSM IP ASSETS B.V.
Reel/Frame 028938/0620 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2011
From: LEE, JUNG; MIKRUT, BERNARD A.; TANG, XUEJUN
To: MARTEK BIOSCIENCES CORPORATION
Reel/Frame 026626/0683 →